Results 21 to 30 of about 1,267 (159)

Computational and synthetic approaches for developing Lavendustin B derivatives as allosteric inhibitors of HIV-1 integrase [PDF]

European Journal of Medicinal Chemistry, 2016
Through structure-based virtual screening and subsequent activity assays of selected natural products, Lavendustin B was previously identified as an inhibitor of HIV-1 integrase (IN) interaction with its cognate cellular cofactor, lens epithelium-derived growth factor (LEDGF/p75).
Fatima Ezzahra Agharbaoui, Ashley C. Hoyte, Stefania Ferro, Rosaria Gitto, Maria Rosa Buemi, James R. Fuchs, Mamuka Kvaratskhelia, Laura De Luca   +7 more
openalex   +3 more sources

Molecular Modeling Study on the Allosteric Inhibition Mechanism of HIV-1 Integrase by LEDGF/p75 Binding Site Inhibitors

PLoS ONE, 2014
HIV-1 integrase (IN) is essential for the integration of viral DNA into the host genome and an attractive therapeutic target for developing antiretroviral inhibitors. LEDGINs are a class of allosteric inhibitors targeting LEDGF/p75 binding site of HIV-1 IN.
Weiwei Xue, Huanxiang Liu, Xiaojun Yao
openalex   +5 more sources

Biological and structural analysis of new potent Integrase-LEDGF allosteric HIV-1 inhibitors [PDF]

, 2023
AbstractLEDGF/p75 (LEDGF) main cellular cofactor of HIV-1 integrase (IN), acts as tethering factor to target integration of HIV in actively transcribed genes. Recently a class of IN inhibitors based on inhibition of LEDGF-IN interaction has been developed.
Erwann Le Rouzic, Damien Bonnard, Frédéric Le Strat, Claire Batisse, Julien Batisse, Céline Amadori, Sophie Chasset, Stéphane Emiliani, Benoît Ledoussal, Marc Ruff, F. Moreau, Richard Benarous   +11 more
openalex   +2 more sources

Development of an AlphaScreen-Based HIV-1 Integrase Dimerization Assay for Discovery of Novel Allosteric Inhibitors [PDF]

SLAS Discovery, 2012
In recent years, HIV-1 integrase (IN) has become an established target in the field of antiretroviral drug discovery. However, its sole clinically approved inhibitor, the integrase strand transfer inhibitor (INSTI) raltegravir, has a surprisingly low genetic barrier for resistance.
Jonas Demeulemeester, Cristina Tintori, Maurizio Botta, Zeger Debyser, Frauke Christ   +4 more
openalex   +5 more sources

Structure-based amelioration of PXR transactivation in a novel series of macrocyclic allosteric inhibitors of HIV-1 integrase

Bioorganic & Medicinal Chemistry Letters, 2020
Previous studies have identified a series of imidazo[1,2-a]pyridine (IZP) derivatives as potent allosteric inhibitors of HIV-1 integrase (ALLINIs) and virus infection in cell culture. However, IZPs were also found to be relatively potent activators of the pregnane-X receptor (PXR), raising the specter of induction of CYP-mediated drug disposition ...
Prasanna Sivaprakasam, Zhongyu Wang, Nicholas A. Meanwell, Javed Khan, David R. Langley, Stephen R. Johnson, Li Guo, Annapurna Pendri, Timothy P. Connolly, Mian Gao, Daniel M. Camac, Cheryl Klakouski, Tatyana Zvyaga, Christopher Cianci, Brian McAuliffe, Bo Ding, Linda Discotto, Mark Krystal, Susan Jenkins, Kevin M. Peese, B. Narasimhulu Naidu   +20 more
openalex   +3 more sources

Structure-function analyses unravel distinct effects of allosteric inhibitors of HIV-1 integrase on viral maturation and integration [PDF]

Journal of Biological Chemistry, 2018
Recently, a new class of HIV-1 integrase (IN) inhibitors with a dual mode of action, called IN-LEDGF/p75 allosteric inhibitors (INLAIs), was described. Designed to interfere with the IN-LEDGF/p75 interaction during viral integration, unexpectedly, their major impact was on virus maturation.
Damien Bonnard, Erwann Le Rouzic, Sylvia Eiler, Céline Amadori, Igor Orlov, Jean‐Michel Bruneau, Julie Brias, Julien Barbion, Francis Chevreuil, Danièle Spehner, Sophie Chasset, Benoît Ledoussal, F. Moreau, Ali Saı̈b, Bruno P. Klaholz, Stéphane Emiliani, Marc Ruff, Alessia Zamborlini, Richard Benarous   +18 more
openalex   +5 more sources

Discovery and Optimization of Novel Pyrazolopyrimidines as Potent and Orally Bioavailable Allosteric HIV-1 Integrase Inhibitors

Journal of Medicinal Chemistry, 2020
The standard of care for HIV-1 infection, highly active antiretroviral therapy (HAART), combines two or more drugs from at least two classes. Even with the success of HAART, new drugs with novel mechanisms are needed to combat viral resistance, improve adherence, and mitigate toxicities.
Li Guo, Nicholas A. Meanwell, Mark Krystal, David R. Langley, B. Narasimhulu Naidu, Prasanna Sivaprakasam, H.A. Lewis, Kevin Kish, Javed Khan, Alicia Ng, George L. Trainor, Christopher Cianci, Ira B. Dicker, Michael Walker, Zeyu Lin, Tricia Protack, Linda Discotto, Susan Jenkins, Samuel W. Gerritz, Annapurna Pendri   +19 more
openalex   +3 more sources

TALEN knockout of the PSIP1 gene in human cells: analyses of HIV-1 replication and allosteric integrase inhibitor mechanism. [PDF]

J Virol, 2014
Fadel HJ, Morrison JH, Saenz DT, Fuchs JR, Kvaratskhelia M, Ekker SC, Poeschla EM.   +6 more
europepmc   +3 more sources

Synthesis of an HIV-1 Integrase Allosteric Site Inhibitor [PDF]

Synfacts, 2019
Philip Kocieński
openalex   +2 more sources

Decision letter: HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors

, 2019
Julie Overbaugh, Eric O. Freed
openalex   +2 more sources